新华制药：获得富马酸伏诺拉生化学原料药上市申请批准通知书

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Venlafaxine, which is primarily used for gastroesophageal reflux disease [1] Group 1 - The approval notification for Fumaric Acid Venlafaxine marks a significant milestone for the company in expanding its product portfolio [1] - The drug is specifically indicated for the treatment of reflux esophagitis, addressing a common gastrointestinal condition [1]